Janssen-Cilag seeks expanded EMA approval for TREMFYA [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
authorisation application for TREMFYA (guselkumab) to treat adults with active ulcerative colitis and Crohn's disease. The applications are based on positive results from the randomised, double-blind, placebo-controlled, multicentre Phase III QUASAR and GALAXI clinical trial programmes in ulcerative colitis and Crohn's disease respectively. The two trials assessed the safety and efficacy of guselkumab in adult patients with moderately to severely active ulcerative colitis or with Crohn's who showed an inadequate response to or intolerance of standard treatment. Guselkumab met the primary endpoint and offered improvements over placebo in symptoms and disease activity measures Its safety profile was in line with the previous findings of the therapy in approved indications. Data from the Phase III GALAXI 2 and 3 studies showed that guselkumab met the co-primary endpoints at week 12. Treatment with guselkumab also offered statistically significant and clinically meaningful imp
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M [Yahoo! Finance]Yahoo! Finance
- How Much Money Can I Get From The Hair Relaxer Lawsuit? [Forbes]Forbes
- Best Los Angeles Mesothelioma Lawyers Of 2024 [Forbes]Forbes
- Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.MarketBeat
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 5/16/24 - Form 424B2
- 5/15/24 - Form 424B2
- 5/14/24 - Form FWP
- JNJ's page on the SEC website